Axcella Health, Inc.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Axcella Health, Inc
- Target Recruit Count
- 41
- Registration Number
- NCT05152849
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Axcella Health, Inc
- Target Recruit Count
- 273
- Registration Number
- NCT04880187
- Locations
- 🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Del Sol Research Management, LLC, Tucson, Arizona, United States
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Axcella Health, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT04816916
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸OMEGA Research Consultants, DeBary, Florida, United States
🇺🇸UF Hepatology Research at CTRB, Gainesville, Florida, United States
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
- Conditions
- Hepatic Insufficiency
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Axcella Health, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04147936
- Locations
- 🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
- Conditions
- To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell DiseaseSickle Cell DisordersSickle Cell DiseaseAnemia, Sickle CellSickle Cell Anemia
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Axcella Health, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT04134299
- Locations
- 🇺🇸
Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States
🇺🇸Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Primary Care research, Atlanta, Georgia, United States
- Prev
- 1
- 2
- Next
News
Hepatic Encephalopathy: Emerging Therapies and Clinical Trials Highlighted
• Several companies are actively developing novel therapies for hepatic encephalopathy (HE), a neuropsychiatric condition resulting from advanced liver dysfunction. • Key players like Salix Pharmaceuticals and Vedanta Biosciences are advancing treatments such as Xifaxan and VE-303, showing promise in clinical trials. • Emerging therapies focus on innovative mechanisms like gut microbiota modulation and ammonia-lowering agents to improve patient outcomes. • Clinical trials are assessing various routes of administration and molecule types to address the unmet needs in HE treatment.